1Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast turnouts [J]. Nature, 2000, 406 (6797): 747-52.
2Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto ehemieal and clinical characterization of the basal-like Subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004, 10(16): 5367- 5374.
3Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negat ive, progesterone receptor(PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype:a population-based study from the California cancer Registry[J]. Cancer, 2007, 109 (9): 1721 - 1728.
4naffty BG, gang Q, Retss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early- stage breast cancer[J].J Clin Oncol, 2006, 24 (36): 5652- 5657.
6Dent R, Trudeau M, Pritchard KI,et al. Triple-negative cancer:clinical features and of recurrence[J]. Clin breast patterns Cancer Res, 2007, 13(15Ptl): 4429- 4434.
7Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women[J].Breast Cancer Res Treat, 2008, 111 (3): 405- 410.
二级参考文献19
1Perou C M, Sorlie T, Eisen M-B, et al. Molecular portraits of human breast tumors [J]. Nature, 2000,406(6797) :747-752.
2van't Veer L J, Dai H, van de Vijver M J, et al. Gene expression profiling predicts clinical outcome of breast cancer [J ]. Nature, 2002,415(6871 ) : 530-536.
3Sotiriou C, Neo S Y, McShane L M, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study [J]. Proc Natl Acad Sci USA, 2003,100(18) : 10393-10398.
4Rakha E A, El-Sayed M E, Green A R, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer, 2007, 109( 1 ) : 25-32.
5Jones C, Nonni A V, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation [ J ]. Br J Cancer, 2001,85 ( 3 ) : 422-427.
6Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004, 10 (16) :5367-5374.
7Banerjee S, Reis-Filho J S, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J]. J Clin Pathol, 2006,59(7):729-735.
8Carey L A, Dees E C, Sawyer L, et al. The triple negative paradox : primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007,13(8) :2329-2334.
9Chu K C, Lamar C A, Freeman H P. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment [J]. Cancer, 2003, 97( 11 ) : 2853-2860.
10Cunningham J E, Butler W M. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis [ J ]. Breast Cancer Res Treat, 2004,88 (2) : 161-176.
